Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

2023170 citationsJournal Article

Authors

Andreas Reif · Goethe University Frankfurt

István Bitter · Semmelweis University

Jozefien Buyze · Goethe University Frankfurt

Kerstin Cebulla · Goethe University Frankfurt

Richard Frey · Goethe University Frankfurt

Dong‐Jing Fu · Goethe University Frankfurt

Tetsuro Ito ·

Abstract

In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).

Topics & Keywords

Treatment of Major Depression Tryptophan and brain disorders Neurotransmitter Receptor Influence on Behavior

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 14, pp. 1298-1309

DOI: 10.1056/nejmoa2304145

Field-Weighted Citation Impact: 41.00